Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Declines By 36.2%

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 172,300 shares, a drop of 36.2% from the February 13th total of 270,200 shares. Approximately 6.5% of the company’s stock are short sold. Based on an average daily volume of 570,800 shares, the short-interest ratio is currently 0.3 days.

Traws Pharma Trading Down 0.7 %

NASDAQ TRAW opened at $2.74 on Monday. The company’s 50 day simple moving average is $5.72. Traws Pharma has a 52-week low of $2.02 and a 52-week high of $24.75. The company has a market capitalization of $10.00 million, a P/E ratio of -0.02 and a beta of 1.42.

Hedge Funds Weigh In On Traws Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of TRAW. Millennium Management LLC bought a new position in shares of Traws Pharma during the fourth quarter valued at approximately $89,000. Renaissance Technologies LLC bought a new position in shares of Traws Pharma during the fourth quarter valued at approximately $89,000. Geode Capital Management LLC bought a new position in shares of Traws Pharma during the fourth quarter valued at approximately $185,000. Boothbay Fund Management LLC bought a new position in shares of Traws Pharma during the fourth quarter valued at approximately $252,000. Finally, Vestal Point Capital LP bought a new position in shares of Traws Pharma during the fourth quarter valued at approximately $666,000. 7.95% of the stock is currently owned by institutional investors.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.